Common TitlePOLAR
Official Title Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
Phase Phase IIB
ClinicalTrials.gov NCT03639311
Treatments
Injectable cabotegravir and Rilpivirine
Injectable cabotegravir and Rilpivirine
Tradename:CabenuvaClass:Long-Acting Injectable RegimensCategories Switch/Simplification
Funding
IndustryViiV Healthcare and Janssen
References
- Mills A, Richmond GJ, Newman C, et al. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy. AIDS. 2022;36:195-203.